Valuation: Celltrion, Inc.

Market Cap 42,815B 29.79B 25.89B 24.1B 22.13B 41.79B 2,844B 42.44B 284B 112B 1,416B 112B 109B 4,747B P/E 2026 *
28.4x
P/E 2027 * 24.5x
Enterprise Value 44.79B 31.16M 27.09M 25.22M 23.15M 43.72M 2.97B 44.4M 297M 117M 1.48B 117M 114M 4.97B EV / Sales 2026 *
8.22x
EV / Sales 2027 * 6.97x
Free-Float
58.02%
Yield 2026 *
0.41%
Yield 2027 * 0.44%
Manager TitleAgeSince
Chief Executive Officer 65 19/03/2015
Chief Executive Officer 42 25/03/2021
President 50 12/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 31/03/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
-0.90%+2.62%+37.06%+10.96% 11.2B
Average -1.40%+0.85%+62.86%+98.89% 25.76B
Weighted average by Cap. -1.54%+1.75%+84.09%+133.35%

Financials

2026 *2027 *
Net sales 5,449B 3.79B 3.3B 3.07B 2.82B 5.32B 362B 5.4B 36.16B 14.19B 180B 14.24B 13.93B 604B 6,325B 4.4B 3.83B 3.56B 3.27B 6.17B 420B 6.27B 41.97B 16.47B 209B 16.53B 16.16B 701B
Net income 1,485B 1.03B 898M 836M 768M 1.45B 98.64B 1.47B 9.86B 3.87B 49.11B 3.88B 3.8B 165B 1,768B 1.23B 1.07B 995M 914M 1.73B 117B 1.75B 11.73B 4.6B 58.46B 4.62B 4.52B 196B
Net Debt 1,978B 1.38B 1.2B 1.11B 1.02B 1.93B 131B 1.96B 13.12B 5.15B 65.39B 5.17B 5.05B 219B 1,262B 878M 764M 711M 653M 1.23B 83.85B 1.25B 8.38B 3.29B 41.74B 3.3B 3.23B 140B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A